Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stratified and optimized treatment for elderly diffuse large B-cell lymphoma
ChiCTR2300074720Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, lenalidomide, zanubrutinib, orelabrutinib, cyclophosphamide and 4 more in diffuse large B-cell lymphoma (DLBCL) (5 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: progression-free survival. Started Aug 2023; status: recruiting.
02
Drugs
rituximablenalidomidezanubrutiniborelabrutinibcyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300074720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074720.